Xoft Inc., an electronic brachytherapy developer, showcases the expanded treatment capabilities of the Axxent eBx System. Xoft’s eBxtechnology delivers a high therapeutic dose to a cancer tumor while sparing nearby normal tissue. With the recent FDA clearance and launch of a new skin and surface treatment applicator, the Axxent System is now being used to treat skin cancer patients and to deliver surface brachytherapy, including Intraoperative Radiation Therapy (IORT).
Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent eBx System is also FDA-cleared for intraoperative delivery to any external or internal surface of the body where radiation therapy is indicated. As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Utilizing a proprietary miniaturized X-ray source rather than radioactive isotopes, the system can be used to deliver radiation in minimally shielded therapeutic settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety.
February 15, 2024 
